| 진행성 비소세포 폐암에 대한 Cisplatin , Etoposide , Vinblastine ( PEV ) 3 제 복합 화학 요법 |
| 박근칠, 강윤구, 신동복, 김시영, 방영주, 한성구, 심영수, 김노경, 김건열, 한용철 |
|
| Combination Chemotherapy with Cisplatin , Etoposide , and Vinblastine ( PEV ) in the Advanced Non - Small Cell Lung Cancer |
| Keun Chil Park, Yoon Koo Kang, Dong Bok Shin, Si Young Kim, Yung Jue Bang, Sung Koo Han, Young Soo Shim, Noe Kyeong Kim, Keun Youl Kim, Keun Youl Kim |
|
|
|
|
|
|
|
| ABSTRACT |
|
Fifty patients with the advanced non-small cell lung cancer, who had no previous treatment, were treated with a combination chemotherapy regimen consisting of cisplatin (20mg/m i.v. day 1-5), etoposide (100 mg/m i.v. day 2-4), and vinblastine (6 mg/m(2) i.v, day 1) every 3 weeks. Among the 50 patients entered into this study 45 patients were evaluable for response. Objective responses were achieved in 49 % (22/45) of patients (2 CRs, 20 PRs). In 23 patients with limited disease, the response rate was 61% (14/23) with no complete response, higher than that, but not statistically significant, in the extensive disease patients (36% with 2 CRs). The overall median survival of the patients was 42.6 weeks and the responding patients survived longer than non-responders (median survival; 51.5 weeks vs. 37.4 weeks, p<0.05). Toxicity with this regimen was acceptable; myelosup- pression was the major toxic effect and was severe in only 11% of the patients with one treatment- related death from sepsis associated with granulocytopenia. The gastrointestinal side effects and alopecia were rather universal and the peripheral neuropathy (20%) and azotemia (9%) were not uncommon, but manageable in general. |
|
PDF Links
Full text via DOI 
Download Citation 
